Colombia’s Glivec Pricing Means “Worst Of Scenarios” For Pharma Industry
Executive Summary
AFIDRO, the association representing Colombia’s research-based pharmaceutical industry, is taking the government to court over new pricing regulations that follow the controversial declaration of public interest for Novartis’ Glivec (imatinib).